首页> 外文期刊>Cancer science. >Oncogenic role of kinesin proteins and targeting kinesin therapy
【24h】

Oncogenic role of kinesin proteins and targeting kinesin therapy

机译:驱动蛋白的致癌作用和靶向驱动蛋白的治疗

获取原文
获取原文并翻译 | 示例
           

摘要

The kinesin superfamily (KIF) is a group of proteins that share a highly conserved motor domain. Except for some members, many KIF proteins have adenosine triphosphatase activity and microtubule-dependent plus-end motion ability. Kinesins participate in several essential cellular functions, including mitosis, meiosis and the transport of macromolecules. Increasing evidence indicates kinesin proteins play critical roles in the genesis and development of human cancers. Some kinesin proteins are associated with maligancy as well as drug resistance of solid tumor. Thus, targeting KIF therapy seems to be a promising anticancer strategy. Inhibitors of KIF such as kinesin spindle protein (KSP/Eg5) have entered clinical trials for monotherapy or in combination with other drugs, and kinesins other than Eg5 with various potential anticancer target characteristics are also constantly being discovered and studied. Here, we summarize the oncogenic roles of kinesin proteins and potential cancer therapy strategies that target KIF.
机译:驱动蛋白超家族(KIF)是一组蛋白质,它们具有高度保守的运动域。除某些成员外,许多KIF蛋白都具有腺苷三磷酸酶活性和微管依赖性正向运动能力。驱动蛋白参与几种基本的细胞功能,包括有丝分裂,减数分裂和大分子的运输。越来越多的证据表明,驱动蛋白在人类癌症的发生和发展中起着至关重要的作用。一些驱动蛋白与实体瘤的旺盛性和耐药性有关。因此,靶向KIF治疗似乎是一种有前途的抗癌策略。 KIF的抑制剂,如驱动蛋白纺锤体蛋白(KSP / Eg5)已进入单一疗法或与其他药物组合的临床试验,并且除Eg5以外的具有多种潜在抗癌靶标特征的驱动蛋白也正在不断地被发现和研究。在这里,我们总结了驱动蛋白的致癌作用和针对KIF的潜在癌症治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号